Blog Tool

Sensydia Awarded Second Phase of $3M NIH Grant Award to Demonstrate Clinical Utility of Cardiac Performance System (CPS™)

The NIH has activated Phase II funding of Sensydia’s Fast-Track STTR grant to support real-world clinical utility studies of the Cardiac Performance System (CPS™). This non-dilutive funding marks a key milestone as the company continues to validate CPS for patients with heart failure and pulmonary hypertension.

Admin

Jun 92 min read

Rusty Page appointed President and Chief Operating Officer of Sensydia.

Sensydia Appoints Rusty Page as President and Chief Operating Officer to Support Growth and Commercialization of the Cardiac Performance System (CPS™)

Industry veteran brings over 20 years of medical device leadership to guide operations, quality, and infrastructure as Sensydia advances toward FDA submission and commercialization of the Cardiac Performance System (CPS™).

Admin

May 62 min read

Sensydia’s Cardiac Performance System (CPS™) is designed for fast, safe, and non-invasive cardiac performance assessment that can be performed almost anywhere, avoiding the need to visit a catheterization lab. Source: Sensydia.

Sensydia Announces First Patient Enrolled in Pivotal Study of Non-Invasive Cardiac Performance System (CPS™)

Sensydia has enrolled the first patient in its pivotal clinical study evaluating the Cardiac Performance System (CPS™), a non-invasive solution for hemodynamic assessment. This milestone advances CPS™ toward FDA submission and supports Sensydia’s mission to transform the management of heart failure and other cardiac conditions through faster, safer diagnostics.

Admin

Apr 282 min read

Clinical data presented at ACC 2025 shows Sensydia CPS™ provides accurate assessment of mean pulmonary artery pressure non-invasively

Completion of this 50-subject study is a key milestone on the path to delivering the first device for non-invasive and accurate...

Admin

Mar 293 min read

Sensydia Completes Fifth Study for Heart-Sound AI

Completion of this 50-subject study is a key milestone on the path to delivering the first device for non-invasive and accurate...

Admin

Jan 16, 20243 min read

Sensydia secures $3M NIH grant to advance AI-based cardiac assessment platform

NIH STTR Fast-Track grant helps propel Sensydia's non-invasive CPS platform building on recent funding round Los Angeles, CA – June 5,...

Admin

Jun 5, 20232 min read

Sensydia raises $8M round to advance breakthrough CPS cardiac assessment platform

Sensydia continues to push the boundaries of AI in heart function assessment Los Angeles, CA – May 9, 2023 – Non-invasive cardiac...

Admin

May 9, 20233 min read

Sensydia Achieves Study Target for Heart-Sound AI

Completion of enrollment for this 225-subject study is a key milestone on the path to delivering the first device for non-invasive and...

Admin

Feb 6, 20233 min read

Sensydia Receives FDA Breakthrough Device Designation for CPS Non-Invasive Cardiac Monitoring Device

External device uses heart sound and AI to deliver rapid cardiac function assessments via tablet to expand hemodynamic evaluation beyond...

Admin

Jan 19, 20222 min read

Sensydia Appoints Anthony Arnold as President and Chief Executive Officer

Los Angeles – October 1, 2019 – Sensydia Corporation, an innovator in rapid, non-invasive measurement of critical cardiac function,...

Admin

Oct 1, 20192 min read

FDA Clears Sensydia’s Cardiac Performance System

The Sensydia Cardiac Performance System (CPS) is the first patient-worn system to provide Ejection Fraction information to clinicians for...

Admin

Jun 18, 20182 min read

Sensydia Completes Series B Financing

Sensydia Corporation announces that it has complete a Series B financing. The financing was led by Colle Capital and included all Series...

Admin

Jul 1, 20171 min read

Sensydia Completes Series A Financing

Sensydia Corporation has completed its first round of financing which will be used to develop its patent pending technology to detect...

Admin

Apr 4, 20161 min read